|
Drug
|
Surface Modifier
|
Modification Rational
|
Reference
|
| Curcumin |
N-trimethyl chitosan |
Burst release of curcumin SLN in an acidic environment was the main obstacle. N-trimethyl chitosan is used as an acid protective coat to prevent the burst release of curcumin SLNs. |
165
|
| Triamcinolone acetonide |
a pH-sensitive derivative of phosphatidylethanolamine |
Tumor and inflamed tissues are having leaky vasculature structures, and also that region is having different acidic pH than normal vasculature. To control the drug release behavior of drug pH, the sensitive coat is done. |
166
|
| Resveratrol |
N-trimethyl chitosan-g -palmitic acid |
The potential application of resveratrol is limited due to its poor aqueous solubility, its photosensitivity, poor absorption properties, and rapid first-pass metabolism. To overcome the problems, it is coated with the N-trimethyl chitosan-g-palmitic acid. |
167
|
| Docetaxel |
Hydroxypropyl trimethylammonium chloride chitosan |
To reduce its first-pass metabolism and increase its solubility SLN of Docetaxel is formulated. However, a negative charge on the SLNs is an obstacle in drug absorption because of the electrostatic repulsion between the cell membrane and SLNs it is coated with positively charged chitosan to reduce the repulsion. |
168
|
| Rifampicin |
Methyl α-D-mannopyranoside |
To increase the targeting of Rifampicin SLN formulation, it is coated with methyl α-D-mannopyranoside |
169
|
| Ifosfamide |
Crosslinked with sodium tripolyphosphate |
Ifosfamide gets degraded in the acidic medium, which is pH-dependent on reducing the degradation of the drug; it is coated and crosslinked with tripolyphosphate. |
170
|
| Retinyl palmitate |
Diacetyl phosphate (DCP) |
Diacetyl phosphate has a negative charge on its surface. This type of charge is known to affect the delivery efficiencies of modified carriers also DCP is considered as a safe excipient to use in a topical preparation. |
171
|
| Paclitaxel |
Hyaluronic acid |
CD44 receptors are present on cancer stem cell (CSCs) which specifically binds to the Hyaluronic acid. |
172
|
| Paclitaxel |
Folate-grafted copolymer of PEG and chitosan |
To increase the circulation time and stability. |
140
|
| Prednisolone |
Hyaluronic acid |
To target, the CD44 receptors are present on synovial lymphocytes in arthritis. |
164
|
